, Volume 12, Issue 4, pp 778–787 | Cite as

Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?

  • Shokouh Arjmand
  • Zohreh Vaziri
  • Mina Behzadi
  • Hassan Abbassian
  • Gary J. StephensEmail author
  • Mohammad ShabaniEmail author


Tremor arises from an involuntary, rhythmic muscle contraction/relaxation cycle and is a common disabling symptom of many motor-related diseases such as Parkinson disease, multiple sclerosis, Huntington disease, and forms of ataxia. In the wake of anecdotal, largely uncontrolled, observations claiming the amelioration of some symptoms among cannabis smokers, and the high density of cannabinoid receptors in the areas responsible for motor function, including basal ganglia and cerebellum, many researchers have pursued the question of whether cannabinoid-based compounds could be used therapeutically to alleviate tremor associated with central nervous system diseases. In this review, we focus on possible effects of cannabinoid-based medicines, in particular on Parkinsonian and multiple sclerosis-related tremors and the common probable molecular mechanisms. While, at present, inconclusive results have been obtained, future investigations should extend preclinical studies with different cannabinoids to controlled clinical trials to determine potential benefits in tremor.


Tremor Cannabinoid Parkinson’s disease Multiple sclerosis Huntington’s disease Ataxia 

Apothecaries were not worth a pin,

If Hemp seed did not bring their commings in;

Oyles, Vnguents, Sirrops, Minerals, and Baulmes,

(All Natures treasures, and th' Almighties almes,)

Emplasters, Simples, Compounds, sundry drugs

With Necromanticke names like fearefull Bugs,

Fumes, Vomits, purges, that both cures, and kils,

Extractions, conserues, preserues, potions, pils,

Ellixers, simples, compounds, distillations,

Gums in abundance, brought from foreigne nations.

John Taylor (1580–1653)

For several millennia, many civilizations have used Cannabis sativa for assorted purposes [1]. This magical plant was eulogized for its recreational use and its tremendous beneficial effects in painless surgeries [2, 3]. To date, >100 terpenophenolic cannabinoids have been isolated from C. sativa, among these, Δ9-tetrahydrocannabinol (Δ9-THC), as the primary and main psychoactive constituent, cannabidiol (CBD), cannabinol, cannabichromene, and cannabigerol are of particular interest [4, 5, 6]. In the light of previous studies, the cannabis plant has been shown to play a role as an antiemetic, appetite stimulant, analgesic, euphoriant, anti-inflammatory agent, anticonvulsant, and as a sedative [2, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20]. It has also been noted that cannabis can impair memory and cognition [21, 22]. However, the clinical applications of cannabis remain circumscribed, largely owing to the known psychoactive effects of Δ9-THC [23, 24]. Cannabinoids exert their pharmacological and physiological activities predominantly through G protein-coupled cannabinoid CB1 and CB2 receptors (CB1R and CB2R, respectively) [25, 26]. Following the discovery of cannabinoid receptors in rat brain in 1980, the location of these receptors was mapped in mammalian species, including humans, and were shown to be ubiquitous in hippocampus, basal ganglia, and cerebellum. Some years later, in 1990 and 1993, CB1R and CB2R, respectively, were cloned [27, 28, 29]. The predominant expression of these receptors, in particular CB1R, and the presence of endocannabinoids in brain areas responsible for the management of movements, such as basal ganglia and cerebellum, together with the conspicuous changes in endocannabinoid transmission in the brains of individuals affected by motor disorders, provides a compelling conceptual argument that cannabinoid-based compounds may have the potential to alleviate symptoms of these diseases and provide a novel area of research [30, 31]. The aim of the current paper is to review the literature on the effects of cannabinoids in motor disorders associated with tremor, with the goal of highlighting possible therapeutic applications. Tremor is a rhythmic, unintentional, oscillatory, and twitching movement, and a clinical manifestation of numerous disorders such as multiple sclerosis (MS), Parkinson’s disease (PD), and Huntington’s disease (HD), which all affect central areas associated with motor control [32, 33, 34]. Tremor has been categorized, based on its etiology, origin, and clinical presentations, into 6 main groups [35]. Despite significant efforts to find an effective pharmacological intervention, as yet there is limited availability of efficient treatments to reduce tremor markedly [36]. However, new insights into the molecular basis of diseases associated with tremor might lead to such a discovery. As argued below, cannabinoids could represent a promising avenue of future research.

Cannabinoid Receptors and Signaling in relations to Central Nervous System Dysfunction Associated with Tremor

Endocannabinoids are produced “on demand” and act as a retrograde messenger on presynaptic cannabinoid receptors. Although additional molecular targets may be involved, cannabinoid receptors have been divided into 2 major subtypes, CB1R and CB2R [26, 37]. While CB2R are mostly found in the immune system, CB1R are highly expressed and localized to several regions of the brain, with reported expression in neurons, oligodendrocytes, astrocytes, and neural stem cells [38, 39, 40, 41, 42, 43, 44, 45, 46]. Owing to this abundance, the potentially greater significance of CB1Rs will be the focus of this review (Table 1).
Table 1

A brief outlook on tremor and cannabinoid-based compounds









 Idiopathic PD

Patients unresponsive to common drugs

Marijuana cigarette

2.9 % Δ9-THC

No changes in tremor

May be useful when anxiety is a trigger factor for tremor in patients


 MPTP model of PD

Adult male cynomolgus monkeys (Macaca fascicularis)


(CB1 agonist)

Dose range 0.01 - 0.1 mg/kg  i.m.

↓ Locomotor activities, ↑ bradykinesia, dose dependently

Failed to produce catalepsy

CB agonists did not induce catalepsy in primates, a finding that differs from their effects in rodents

Primates may be more suitable than rodents for predicting the effects of cannabinoids and their therapeutic potential



(CB1 antagonist)

Low and high dose:


and 3.0 and 6.0 mg/kg

Failed to alleviate motor deficits


L-DOPA-treated patients

WIN 55,212-2

(CB1 agonist)

5 μM

↑ [35S]GTPγS binding in caudate nucleus, putamen, lateral globus pallidus, and substantia nigra

↑ CB1R binding in caudate nucleus and putamen but no changes in lateral globus pallidus and substantia nigra

More effective activation of G-protein-coupled signalling mechanisms via CB1R

Nigro-striatal lesion →↑ CB1Rs in basal ganglia in humans and nonhuman primates

This increase could be reversed by chronic L-DOPA therapy

CB1R blockade might be useful as an adjuvant for treatment of Parkinsonian motor symptoms


 MPTP model of PD

Marmoset with and without chronic L-DOPA treatment


↑ Stimulation of [35S]GTPγS

↑CB1R binding in caudate nucleus and putamen

Following L-DOPA treatment, these parameters returned to control values.



questionnaire-based study



45.9 % described some form of benefit

30.6 % improvement of rest tremor




Mice mutants

Deletion of genes associated with development of PD in humans:



Biphasic pattern in CB signalling during progression of PD:

early stages→ desensitization/downregulation of CB1R

Intermediate and advanced stages → upregulatory responses of CB1R, possibly also CB2R, and their endocannabinoid ligands

Losses may be part of the pathogenesis itself

CB1R antagonists potentially attenuate the bradykinesia, typical of PD


 HPD by 6-OHDA and

 Parkinsonian tremor by tacrine

Adult male Sprague–Dawley rats

A2A antagonists (MSX-3 or SCH58261) + CB1 antagonists (rimonabant) + L-DOPA

2 or 3 mg/kg


1 mg/kg


3 mg/kg


A2A antagonists produce similar behavioural effects to CB1 antagonists

Combined A2A–CB1 antagonist (SCH58261–rimonabant) →↓ only tremor bursts.

Rimonabant potentiates L-DOPA effects on contralateral adjusting step impairment in HPD rats

In striatal glutamatergic terminals CB1-mediated inhibition of glutamate release due to A2A activation may also result from an interaction at

second messenger level → complex relationships between CB1R and A2AR in locomotion




open-labeled study

Smoking cannabis

0.5 g inhaled

↓ Tremor, rigidity and bradykinesia





Patients disabled with tremor and ataxia

Oral Δ9-THC


25 % patients demonstrated improved motor coordination.




30-year-old patient

Marijuana cigarette

One marijuana cigarette

Hours after “experimental” cigarette, action tremor abolished

Acute improvement

Powerful beneficial effects on both spasticity and ataxia



Patients questionnaire-based study



From 97 % to 30 %, the patients reported that cannabis improved (in descending rank order) spasticity, chronic pain of extremities, acute paroxysmal phenomenon, tremor, emotional dysfunction, anorexia/weight loss, fatigue states, double vision, sexual dysfunction, bowel and bladder dysfunctions, vision dimness, dysfunctions of walking and balance, and memory loss


 CREAE model of MS


R(+)-WIN 55,212-2,

(CB1R agonist):

Δ9-THC, methanandamide


2.5 mg/kg, 5.0 mg/kg i.p.; 10.0,

5.0 mg/kg,

1.5 mg/kg i.v.

Quantitatively ameliorated both tremor and spasticity

Endocannabinoid system may be tonically active in the control of tremor and spasticity.



SR141716A, SR144528

(CB antagonist)

5 mg/kg


Exacerbation of both tremor and spasticity




Oral cannabis extract (n = 211)

Δ9-THC (n = 206)

15 weeks

48 %, 40 %, and 33 % recuperation in tremor of patients consuming cannabis extract, Δ9-THC, and placebo, respectively, but nonsignificant


 MS and upper limb tremor


Oral Cannador

4 weeks

No improvement for upper limb tremor and 5 patients felt a subjective improvement of tremor whilst on active treatment.



160 outpatients

double-blind, randomized, placebo-controlled

Whole-plant CBME containing equal amounts of Δ9-THC and CBD

Oromucosal sprays 2.5–120.0 mg of each daily, in divided doses

No significant reduction in primary symptoms

Spasticity significantly reduced



Patient with MS

Oral cannabis extract (Cannador)

10 weeks

Not functionally significant, only subjective improvement in tremor



Single case report of patient

Marijuana smokers

Acute improvement of chronic motor handicap


160 patients with MS


No objective improvement of tremor

 Progressive EAE model of MS

Female mice C57BL/6

murine model of MS

WIN 55,512-2

(CB agonist)

5 mg/kg


↓ progression of symptoms (tremor, spasticity, and pain)

WIN 55,212-2 effects in EAE by activation of CB1 not CB2


Antagonists of CB1(rimonabant) or CB2 ( AM-630)

Reversion of positive effects of WIN 55,512-2 on neurological decline with rimonabant, not AM630


(CB2 agonist)

No positive effects on neurological decline in EAE



15 neuroleptic-free patients


10 mg/kg/day for 6 weeks


An average daily dose of 700 mg/day for 6 weeks was not symptomatically effective in neuroleptic-free HD patients

CBD has a low affinity for CB1R compared with other CBs

CBD behaves as an antagonist in the micromolar range



Postmortem human tissue


synthetic cannabinoid

10 nM

Relative preferential loss/dysfunction of striatal neurons projecting to lateral pallidum compared to medial pallidum

CBR-containing terminals in lateral pallidum may be affected earlier/more severely than in medial pallidum; both pallidal segments may be affected before/more severely than cell bodies or dendrites in striatum




drug-free man

Nabilone (CB agonist)

1.5 mg

↑ choreatic movement

Worsening effect on HD


 3-NP model of HD

Adult male Sprague–Dawley rat


(endocannabinoid uptake inhibitor)

10 mg/kg


↓motor disturbances observed in the early phase of hyperactivity

induced recovery in GABA and dopamine deficiency induced by toxin in the basal ganglia

Biphasic motor disturbances, with an early (1–2 week) hyperactivity followed by a late (3–4 weeks) motor depression and a loss of CB1R in the basal ganglia of HD rats



44 randomized patients


1 or 2 mg

A treatment difference of 0.86 (95 % CI –1.8 to 3.52) for total

motor score;

1.68 (95 % CI 0.44–2.92) for chorea

Change in motor symptoms of HD was small

Did not exacerbate chorea


 3-NP and malonate model of HD

Adult male Sprague–Dawley


Δ9-THC–CBD-enriched botanical extracts combined in a ratio of 1:1

4.63 mg/kg

↓3-NP-induced GABA deficiency, loss of Nissl-stained neurons, downregulation of CB1R

These effects are probably related to antioxidant and CBR independent properties of both phytocannabinoids


CB antagonists:



1 mg/kg

Positive effect of phytocannabinoids, not reversed by CB antagonists

 3-NP model of HD

N171-82Q transgenic model

Genetic deletion of CB1R


Worsened motor performances in N171-82Q mice and

↑susceptibility to 3-NP toxin for HD induction



 Patients with MS disabled by tremor and ataxia

8 patients

CB agonists:


Dose range:

5–15 mg


two patients demonstrated improved motor coordination


 Patients with MS

Clinical rating, EMG of leg flexor reflexes and electromagnetic recording of hand action tremor



Acute improvement of chronic motor handicaps


 Microinjection via implanted stainless steel guide cannulas

Male CD-1 mice

Synthetic CB agonists: CP55,940

and HU-210

CB1 antagonist:


intracerebellar (i.c.b.)

(5–25 μg)

(1.56–6.25 μg)

(25 μg)

Dose-dependent motor incoordination elicited by HU-210 (6.25 μg) and CP55,940 (20 μg) was significantly blocked by SR141716A (25 μg)

Cannabinoid-induced motor impairment occurs by activation of CB1 receptor in cerebellum


 Model of motor impairment

Male ICR albino mice

CB1 agonists: CP55940,

WIN 55,212-2,


AEA: 2 AEA analogs (ACEA and ACPA)

CB1 antagonist:


(1, 3)

10, (30, 100) mg/kg i.p.

(3-10) mg/kg i.v.

(1, 5) mg/kg i.p.

All CB1 receptor agonists → ↑ in gait width (truncal ataxia) and number of slips in the bar cross test (motor incoordination)

Pretreatment with SR141716 → ↓ both the change in gait width and number of slips induced by CP55940 and AEA

Neither cannabidiol nor WIN 55,212-2 affected measures

This effect is mediated by the CB1 receptor

The assays used in this study are specific for cerebellar-mediated behavioral deficits, so these deficits are not mediated by the basal ganglia or cannabinoid-induced alterations in nigrostriatal dopaminergic transmission


 Animal models of cerebellar ataxia display

“Ducky” du2J mouse


Du2J ataxia model is associated with deficient CB1 signalling in the cerebellar cortex, putatively linked with compromised Ca2+ channel activity and the ataxic phenotype


PD = Parkinson’s disease; Δ9-THC = Δ9-tetrahydrocannabinol; MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; CB = cannabinoid; i.m. = intramuscularly; L-DOPA = levodopa; GTPγS = nonhydrolyzable G-protein-activiating analog of guanosine triphosphate; CB1R = cannabinoid receptor type 1; 6-OHDA = oxidopamine; A2A = adenosine A2A receptor; MSX-3 = Selective A2A adenosine receptor antagonist; i.p. = intraperitoneally; HPD = Hemi-Parkinson’s disease; A2AR = A2A receptor; MS = multiple sclerosis; CREAE = chronic/relapsing experimental allergic encephalomyelitis; i.v. = intravenously; CBME = cannabis-based medicinal extract; CBD = cannabidiol; EAE = experimental autoimmune encephalomyelitis; HD = Huntingdon’s disease; p.o. = per os (i.e., orally); 3-NP = 3-nitropropionic acid; GABA = γ-aminobutyric acid; CI = confidence interval; EMG = electromyography; (i.c.b.) = intracerebellar; ICR = Institute for Cancer Research; AEA = N-arachidonoylethanolamine; ACEA = Arachidonoyl 2'-chloroethylamide; ACPA = Arachidonoyl Cyclopropylamide

The notably high expression of CB1R in the cerebellum, in particular on inputs into Purkinje cells from inhibitory basket and stellate interneurons and excitatory climbing fibers arising from granule cells, is indicative of the crucial role of CB1R in cerebellar function. Moreover, it has been shown that CB1R knockout mice, as well as chronic marijuana users or animals administered CB1R agonists, have clear impairment of eyeblink conditioning, an epitome of cerebellar cortex function [47, 48, 49, 50, 51]. 2-Arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA), 2 arachidonic acid derivatives, are the chief endocannabinoids in the brain; cerebellum CB1R are predominantly activated by 2-AG. An increase in the concentration of postsynaptic Ca2+ either by entry via voltage-gated Ca2+ channels or activation of type 1 metabotropic glutamate receptors brings about the release of 2-AG synthesized from diacylglycerol, a reaction catalyzed by diacylglycerol lipase-alpha in Purkinje cells, with the overall effect of activation of presynaptic CB1R [52, 53, 54, 55, 56]. In addition, several studies have reported the high density of CB1Rs in striatum and the presence of AEA throughout the basal ganglia, in particular in the globus pallidus and substantia nigra [31, 57, 58]. The crosstalk between dopaminergic transmission and endocannabinoids signaling in the striatum nigra is also well established and there is a growing body of evidence that CB1R activation by endocannabinoid retrograde signaling has the potential to decrease glutamate release in a dopaminergic D2 receptor-dependent manner [59, 60, 61].

Cannabinoids and Tremor in PD

PD is a progressive neurodegenerative disease affecting basal ganglia and characterized by tremor, rigidity, bradykinesia, and muscle stiffness [62, 63, 64]. The piecemeal loss of melanin-containing nigral neurons leads to aberrant dopaminergic transmission, with tremor emerging as a consequence of subthalamic overactivity [64, 65, 66, 67, 68, 69]. The increase in the levels of endocannabinoids and alteration in both CB1R and CB2R expression in different stages of PD opens the possibility of manipulation of receptor function in the management of disease [64, 70]. Studies have demonstrated that, in the early stages of PD, CB1R are downregulated, while in advanced and symptomatic phases there is a switch to CB1R upregulation [71]. These findings may suggest a basis for use of cannabinoid antagonists in order to alleviate the motor deficits associated with advanced PD. Despite findings supporting this suggestion, Meschler et al. [72] failed to show the proficiency of the CB1R antagonist SR141716A (rimonabant) in the mitigation of symptoms in a nonhuman primate model of PD. In another study using tacrin, an acetylcholinesterase inhibitor, to induce Parkinsonian tremor, pretreatment with rimonabant was without significant effect on tremor bursts, whereas, in combination with the adenosine A2A receptor antagonist, SCH58261, a marked reduced in tremor bursts was seen [73]; however, it is of note that SCH58261 per se produced a pronounced decrease in tremor bursts. Moreover, an early clinic report suggests no advantageous effects of cannabis on tremor among 5 unresponsive patients to anticholinergics and beta blockers [74]. By contrast, a questionnaire-based study revealed a 30.6 % improvement in rest tremor in tremulous patients with PD [75]. A plausible argument for using cannabinoid agonists as therapeutic agents has arisen from studies describing the inhibitory effect of CB1R activation on glutamate release and its capability to oppose subthalamonigral neuronal overactivity and subsequently reduce tremor [64, 76, 77]. It has also been suggested that cannabinoid agonists and endocannabinoids can block dopamine transporters and thereby inhibit dopamine reuptake to ameliorate dyskinesia [78, 79, 80]. However, there are other studies asserting no beneficial effects of cannabinoid agonists in alleviation of motor symptoms [75, 81, 82, 83].

Unfortunately, there are currently only few double-blind controlled studies and those that have been performed are often paradoxical. In a recent small, open-labeled observational study, the efficacy of cannabis treatment on patients who had experienced severe PD-related pain and tremor, and whose symptoms were insufficiently controlled with current anti-Parkinson medications, was assessed [84]; the results indicated a significant improvement in tremor and rigidity, with a lesser beneficial effect on bradykinesia, among cannabis smokers. Currently, an observational prospective clinical trial is underway to scrutinize the impact of cannabis on PD tremor ( identifier: NCT02028858); such trials should help advance, and resolve, controversies in this field. Despite these conflicting results, cannabinoid-based compounds should not be neglected as a treatment strategy. It seems that alterations to the endocannabinoid system may play a role in Parkinsonian tremor pathogenesis and that more studies are requisite to consider a further range of individual cannabinoids as potential therapeutic agents for managing signs and symptoms of PD, in particular, tremor.

Cannabinoids and MS-related Tremor

There is much anecdotal evidence that patients self-medicate with marijuana with the intention of palliating pain, tremor, spasticity, ataxia, and other symptoms associated with MS, an autoimmune disease typified by demyelination and remyelination, and associated with neuroaxonal damage and inflammation [67, 69, 85, 86]. More recent controlled studies, both in animal models of MS and in humans, have begun to validate these preclinical and uncontrolled observations. Involvement of the endocannabinoid system acting at CB1R in the pathogenesis of MS have been supported by several studies [87, 88, 89, 90]. There are now several lines of evidence indicative of therapeutic potentials of cannabinoids in the control of MS-related symptoms, including tremor, which remains difficult to manage with current medications (e.g., carbamazepine, propranolol, primidone, and gluthetimide) [12, 89, 91, 92]. Following this premise, De Lago et al. [93] have shown that the nonselective cannabinoid agonist WIN 55,212-2 ameliorated neurological disability, tremor, and spasticity in the chronic relapsing experimental autoimmune encephalomyelitis murine model of MS [92]. Correspondingly, this study revealed the prominent role of CB1R activation in the relief of tremor and spasticity, as a selective CB1R, but not a CB2R, antagonist reversed the positive effects of preadministered cannabinoids; moreover, no beneficial effects were observed by administering a selective CB2 agonist [93, 94]. An earlier study reported that cannabinoid agonists Δ9-THC, methanandamide, R(+)WIN 55,212-2, and JWH-133 all diminished tremor and spasticity in the experimental autoimmune encephalomyelitis model, and that aggravation of the symptoms occurred after using CB2R and, in particular, CB1R antagonists [12].

There is also an animal study that supports previous findings which report that chronic, but not acute, Δ9-THC-rich extracts are effective in reducing tremor and spasticity [95]. The “cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis” (CAMS) study, where 611 of 630 patients were followed, reported 48 %, 40 %, and 33 % recuperation in tremor of patients consuming cannabis extract, Δ9-THC, and placebo, respectively; however, the difference in perception of tremor improvement was not statistically significant [96]. A double-blind randomized placebo controlled study failed to show any favorable effects of a cannabis-based medicinal extract on tremor in a subgroup of 13 patients [97, 98]. In addition, although placebo recipients showed faster finger tapping than that of cannabis extract recipients in a randomized double-blind crossover trial amongst 14 tremulous patients, the study was unable to show any overall marked improvement on measures of objective tremor [99]. In a systematic review published by Koppel et al. [100], oral cannabis extract and Δ9-THC was considered, at present, “probably ineffective” and Sativex (nabiximols) “possibly ineffective” for easing MS-related tremors [100]. Although a decrease in CB1R density has been found in caudate–putamen and cortical regions, there are still lack of convincing data on changes to CB1R and CB2R expression and endocannabinoid transmission in both animals and postmortem brain of patients suffering from MS [12, 101].

Cannabinoids and HD-related Tremor

HD is an autosomal dominant, progressive neurodegenerative disorder primarily affecting cortical and striatal neurons [102, 103]; HD is characterized by chorea, that is, jerky involuntary movements (from the Greek word khoreia meaning “dancing in unison”). The loss of CB1R during the progression of HD, most specifically in the lateral pallidum, in transgenic mouse models of HD and in postmortem basal ganglia of patients who suffered from HD, represents a possible justification to investigate the use of cannabinoid agonists in HD [104, 105, 106, 107]. While a beneficial response in reducing chorea has been reported for CBD [108], a controlled clinical trial among 15 patients with HD showed no significant improvements in chorea severity after 6 weeks of CBD administration at an average daily dose of 700 mg/day [109, 110]. In 2 uncontrolled single-patient, single-dose studies, nabilone produced opposing effects, worsening the symptoms and increasing choreatic movements in one study, but improving symptoms in the other [111, 112, 113]. A recent randomized, double-blind, placebo-controlled, crossover study also indicated the effectiveness of nabilone in the improvement in chorea [114]. It should be pointed out that none of these studies has investigated disease progression and they have all used a single cannabinoid. Therefore, data from animal models suggest either that combinations of different cannabinoids or a broad-spectrum cannabinoid may be needed to justify the lack of positive findings in some of the mentioned studies [115, 116].


Ataxias are a group of related neurological movement disorders that affect coordination, balance, and speech, and can also be associated with tremor. It is well known that cannabinoid agonists can induce motor dysfunction in the cerebellum to give an ataxic phenotype in animals, with effects ameliorated by selective CB1R antagonists [117, 118]. To date, there have been no published clinical trials on effects of cannabinoids in ataxia and potential effects on ataxia are confined to case report data in patients with MS with associated ataxia. Here, oral Δ9-THC or marijuana have been reported to improve motor coordination in some patients with MS [89, 92]. These reports contrast with the clear exacerbating effects of CB1R agonists in animals and suggest that investigations with different cannabinoids in patient populations with specific ataxias are needed. In one preclinical model, namely, the “ducky” du 2J mouse model of ataxia and absence epilepsy, it was found that the prominent CB1R-mediated inhibition of GABAergic transmission at interneuron–Purkinje cell synapses seen in the wild type was completely absent in heterozygous and homozygous du 2J mice, despite CB1R expression being unchanged [119] . du 2J mice are deficit in the auxiliary Ca2+ channel subunit α2δ2, and these data are consistent with this deficit leading to aberrant CB1R signaling downstream of receptor activation; it is also possible that deficits in endocannabinoid modulation of inhibitory transmission in the cerebellum contribute to the ataxic phenotype seen here.

Concluding Remarks

Cannabinoids, proposed to act predominantly via CB1R and CB2R activation, have been evaluated for different medical purposes. Cannabinoid receptors and endocannabinoids are highly abundant in the brain areas involved in the management of motor function, and their significant role in modulating many motor functions has been detailed. Although the exact molecular mechanisms of cannabinoid signaling in the pathogenesis of motor-related diseases has not been fully elucidated, and there are significant gaps in our understandings of their influence on motor pathways, medical cannabis appears to have benefits among some patients enduring tremor-associated diseases. However, no studies have so far investigated the role of cannabinoids in essential tremor. At present, despite much anecdotal evidence, observations from case studies and controlled human trials remain poorly matched with those in animal models of diseases. In order to better bridge this gap, it will be important to elucidate mechanisms of cannabinoid action and use comprehensive controlled studies to determine the impact of different cannabinoid-based compounds on tremor-related diseases in both animal models and humans. Furthermore, many clinical studies have reported psychoactive side effects of cannabinoids and hence their introduction in clinical use remains somewhat controversial. Therefore, there is a need to improve and develop novel therapeutic strategies using cannabinoid-based medicines with fewer side effects. In this regard, non-Δ9-THC cannabinoids may provide an attractive alternative. Moreover, while the above mentioned studies have largely focused on exogenous cannabinoid and endocannabinoid effects on CB1R in the central nervous system, it is important to point out that cannabinoid compounds may also act at alternative molecular targets [120]; in particular, the major phytocannabinoid, CBD, has only low, pharmacologically irrelevant, affinity at CB1R and is not associated with psychoactive effects. CBD was recent given orphan drug status for Dravet syndrome and warrants further investigation here, as do other non-Δ9-THC phytocannabinoids, to determine which may be friends and which may be foes in the aim of combating tremor. Given the foregoing considerations, it is reasonable to conclude that cannabinoids represent potential candidates for the management of tremor in some patients with motor-related diseases but that more studies should be done in order to elucidate alterations in cell signaling in both basal ganglia and cerebellum of animal models treated with cannabinoids with the aim of reducing tremors.



We thank Benjamin J. Whalley for his invitation.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Conflicts of interest

GJS has been in receipt of previous funding awards from GW Pharmaceuticals and Ataxia UK.

Supplementary material

13311_2015_367_MOESM1_ESM.pdf (1.2 mb)
ESM 1 (PDF 1229 kb)
13311_2015_367_MOESM2_ESM.pdf (1.2 mb)
ESM 2 (PDF 1268 kb)


  1. 1.
    Giacoppo S, Mandolino G, Galuppo M, et al. Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules 2014;19:18781-18816.PubMedCrossRefGoogle Scholar
  2. 2.
    Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006;28:153-157.PubMedCrossRefGoogle Scholar
  3. 3.
    Walker AWH. Indian hemp and insanity in Egypt. BMJ 1983;2:969-969.CrossRefGoogle Scholar
  4. 4.
    De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479-1494.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 2010;95:434-442.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Tellioglu T, Celebi F. Synthetic marijuana: a recent turmoil in substance abuse. Bull Clin Psychopharmacol 2014;24:396-404.Google Scholar
  7. 7.
    Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002;95:127-135.PubMedCrossRefGoogle Scholar
  8. 8.
    Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012;21:344-352.PubMedCrossRefGoogle Scholar
  9. 9.
    Martin RS, Luong LA, Welsh NJ, et al. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharmacol 2000;129:1707-1715.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Marco EM, Viveros MP. [Functional role of the endocannabinoid system in emotional homeostasis]. Rev Neurol 2009;48:20-26 (in Spanish).PubMedGoogle Scholar
  11. 11.
    Järvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002;95:203-220.PubMedCrossRefGoogle Scholar
  12. 12.
    Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-87. dPubMedCrossRefGoogle Scholar
  13. 13.
    Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2008;56:1059-1068.CrossRefGoogle Scholar
  14. 14.
    Florek-Luszczki M, Wlaz A, Kondrat-Wrobel MW, et al. Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. J Neural Transm 2014;121:707-715.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Moulin DE, Clark AJ, Gilron I, Ware MA. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791-802.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008;4:245-259.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Fichna J, Bawa M, Thakur GA, et al. Cannabinoids Alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. PLoS One 2014;9:e109115.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Silva GD, Lopes PS, Fonoff ET, Pagano RL. The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain? J Neuroinflammation 2015;12:1-11.CrossRefGoogle Scholar
  20. 20.
    Foltin RW. The behavioral pharmacology of anorexigenic drugs in nonhuman primates: 30 years of progress. Behav Pharmacol 2013;23:461-477.CrossRefGoogle Scholar
  21. 21.
    Galarreta M, Erdélyi F, Szabó G, Hestrin S. Cannabinoid sensitivity and synaptic properties of 2 GABAergic networks in the neocortex. Cereb Cortex 2008;18:2296-2305.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Shabani M, Divsalar K, Janahmadi M. Destructive effects of prenatal WIN 55212-2 exposure on central nervous system of neonatal rats. Addict Health 2012;4:9-19.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci 2014;97:55-63.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev 2014;46:72–85.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002;68-69:619-631.PubMedCrossRefGoogle Scholar
  26. 26.
    Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006;30(Suppl. 1):S13-S18.CrossRefGoogle Scholar
  27. 27.
    Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.PubMedCrossRefGoogle Scholar
  28. 28.
    Griffin G, Tao Q, Abood ME. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 2000;292:886-894.PubMedGoogle Scholar
  29. 29.
    Gérard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991;279:129-134.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Razavinasab M, Shamsizadeh A, Shabani M, et al. Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of Parkinson’s disease. Fundam Clin Pharmacol 2013;27:632-640.PubMedCrossRefGoogle Scholar
  31. 31.
    Fernández-Ruiz J, Gonzáles S. Cannabinoid control of motor function at the basal ganglia. Handb Exp Pharmacol 2005;168:479-507.PubMedCrossRefGoogle Scholar
  32. 32.
    Bhidayasiri R. Differential diagnosis of common tremor syndromes. Postgrad Med J 2005;81:756-762.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Anouti A, Koller WC. Tremor disorders. Diagnosis and management. West J Med 1995;162:510-513.PubMedCentralPubMedGoogle Scholar
  34. 34.
    Puschmann AWZ, Puschmann A, Wszolek ZK. Diagnosis and treatment of common forms of tremor. Semin Neurol 2011;31:65-77.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Smaga S. Tremor. Am Fam Physician 2003;68:1545-1553.PubMedGoogle Scholar
  36. 36.
    Schneider SA, Deuschl G. The treatment of tremor. Neurotherapeutics 2014;11:128-138.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Howlett AC, Breivogel CS, Childers SR, et al. Cannabinoid physiology and pharmacology: 30 Years of progress. Neuropharmacology 2004;47:345-358.PubMedCrossRefGoogle Scholar
  38. 38.
    Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 2006;8:E298-E306.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Marcaggi P. Cerebellar endocannabinoids: retrograde signaling from Purkinje cells. Cerebellum 2015;14:341-353.PubMedCrossRefGoogle Scholar
  40. 40.
    Aguado T, Monory K, Palazuelos J, et al. The endocannabinoid system drives neural progenitor proliferation. FASEB J 2005;19:1704-1706.PubMedGoogle Scholar
  41. 41.
    Egertová M, Elphick MR. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 2000;422:159-171.PubMedCrossRefGoogle Scholar
  42. 42.
    Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990;87:1932-1936.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.PubMedCrossRefGoogle Scholar
  44. 44.
    Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003;302:84-88.PubMedCrossRefGoogle Scholar
  45. 45.
    Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 2001;21:823-833.PubMedGoogle Scholar
  46. 46.
    Molina-Holgado E, Vela JM, Arévalo-Martín A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002;22:9742-9753.PubMedGoogle Scholar
  47. 47.
    Skosnik PD, Edwards CR, O’Donnell BF, et al. Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning. Neuropsychopharmacology 2008;33:1432-1440.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Kishimoto Y, Kano M. Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning. J Neurosci 2006;26:8829-8837.PubMedCrossRefGoogle Scholar
  49. 49.
    Steinmetz AB, Edwards CR, Vollmer JM, et al. Examining the effects of former cannabis use on cerebellum-dependent eyeblink conditioning in humans. Psychopharmacology (Berl) 2012;221:133-141.CrossRefGoogle Scholar
  50. 50.
    Steinmetz AB, Freeman JH. Central cannabinoid receptors modulate acquisition of eyeblink conditioning. Learn Mem 2010;17:571-576.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Yeo CH, Hardiman MJ, Glickstein M. Classical conditioning of the nictitating membrane response of the rabbit. I. Lesions of the cerebellar nuclei. Exp Brain Res 1985;60:87-98.PubMedCrossRefGoogle Scholar
  52. 52.
    Blankman JL, Cravatt BF. Chemical probes of endocannabinoid metabolism. Pharmacol Rev 2013;65:849-871.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Yoshida T, Fukaya M, Uchigashima M, et al. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 2006;26:4740-4751.PubMedCrossRefGoogle Scholar
  54. 54.
    Tanimura A, Yamazaki M, Hashimotodani Y, et al. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase α mediates retrograde suppression of synaptic transmission. Neuron 2010;65:320-327.PubMedCrossRefGoogle Scholar
  55. 55.
    Ohno-Shosaku T, Kano M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol 2014;29:1-8.PubMedCrossRefGoogle Scholar
  56. 56.
    Gao Y, Vasilyev DV, Goncalves MB, et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 2010;30:2017-2024.PubMedCrossRefGoogle Scholar
  57. 57.
    Di Marzo V, Breivogel CS, Tao Q, et al. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000;75:2434-2444.PubMedCrossRefGoogle Scholar
  58. 58.
    Herkenham M, Lynn A, Johnson M, et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-583.PubMedGoogle Scholar
  59. 59.
    Pertwee RG, Howlett a C, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev 2010;62:588-631.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Calabresi P, Picconi B, Tozzi A, et al. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci 2014;17:1022-1030.PubMedCrossRefGoogle Scholar
  61. 61.
    Van Der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003;480:133-150.PubMedCrossRefGoogle Scholar
  62. 62.
    Sethi KD. Clinical aspects of Parkinson disease. Curr Opin Neurol 2002;15:457-460.PubMedCrossRefGoogle Scholar
  63. 63.
    Farlow J, Pankratz ND, Wojcieszek J, Foroud T. Parkinson disease overview. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds) GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993–2015. 2004 May 25 [updated 2014 Feb 27].Google Scholar
  64. 64.
    García-Arencibia M, García C, Fernández-Ruiz J. Cannabinoids and Parkinson’ s disease. CNS Neurol Disord Drug Targets 2009;8:432-439.PubMedCrossRefGoogle Scholar
  65. 65.
    Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson’s disease. Prog Neurobiol 2000;62:63-88.PubMedCrossRefGoogle Scholar
  66. 66.
    Schapira AHV, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010;6:309-317.PubMedCrossRefGoogle Scholar
  67. 67.
    Chiurchiù V, Maccarrone M. Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2011;15:2605-2641.PubMedCrossRefGoogle Scholar
  68. 68.
    Romero J, Lastres-Becker I, de Miguel R, et al. The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 2002;95:137-152.PubMedCrossRefGoogle Scholar
  69. 69.
    Chiurchiù V, Leuti A, Maccarrone M. Cannabinoid signaling and neuroinflammatory diseases: a melting pot for the regulation of brain immune responses. J Neuroimmune Pharmacol 2015;10:268-280.PubMedCrossRefGoogle Scholar
  70. 70.
    Lastres-Becker I, Cebeira M, de Ceballos ML, et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson’s syndrome and of MPTP-treated marmosets. Eur J Neurosci 2001;14:1827-1832.PubMedCrossRefGoogle Scholar
  71. 71.
    García-Arencibia M, García C, Kurz A, et al. Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. J Neural Transm Suppl 2009;(73):269-275.PubMedGoogle Scholar
  72. 72.
    Meschler JP, Howlet TAC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl) 2001;156:79-85.CrossRefGoogle Scholar
  73. 73.
    Pinna A, Bonaventura J, Farré D, et al. L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. Exp Neurol 2014;253:180-191.PubMedCrossRefGoogle Scholar
  74. 74.
    Frankel JP, Hughes A, Lees AJ, Stern GM. Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990;53:436.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Venderová K, Ružička E, Vorřísšek V, Višňovský P. Survey on cannabis use in Parkinson’s disease: Subjective improvement of motor symptoms. Mov Disord 2004;19:1102-1106.PubMedCrossRefGoogle Scholar
  76. 76.
    Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999;65:703-713.PubMedCrossRefGoogle Scholar
  77. 77.
    Sañudo-Peña MC, Patrick SL, Khen S, et al. Cannabinoid effects in basal ganglia in a rat model of Parkinson’s disease. Neurosci Lett 1998;248:171-174.PubMedCrossRefGoogle Scholar
  78. 78.
    Price DA, Owens WA, Gould GG, et al. CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem 2007;101:389-396.PubMedCrossRefGoogle Scholar
  79. 79.
    Chen N, Appell M, Berfield JL, Reith MEA. Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. Eur J Pharmacol 2003;478:89-95.PubMedCrossRefGoogle Scholar
  80. 80.
    Heumann R, Moratalla R, Herrero MT, et al. Dyskinesia in Parkinson’s disease: Mechanisms and current non-pharmacological interventions. J Neurochem 2014;130:472-489.PubMedCrossRefGoogle Scholar
  81. 81.
    Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabis in movement disorders. Forsch Komplementarmed 1999;6(Suppl. 3):23-27.PubMedCrossRefGoogle Scholar
  82. 82.
    Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998;5:534-551.PubMedCrossRefGoogle Scholar
  83. 83.
    Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson’s disease: controversies and future approaches. Mov Disord 2015;30:150-159.PubMedCrossRefGoogle Scholar
  84. 84.
    Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non–motor symptoms of Parkinson disease. Clin Neuropharmacol 2014;37:41-44.PubMedCrossRefGoogle Scholar
  85. 85.
    Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517.PubMedCrossRefGoogle Scholar
  86. 86.
    Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-48.PubMedCrossRefGoogle Scholar
  87. 87.
    Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7:39-50.PubMedCrossRefGoogle Scholar
  88. 88.
    Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345:579.PubMedCrossRefGoogle Scholar
  89. 89.
    Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983;13:669-671.PubMedCrossRefGoogle Scholar
  90. 90.
    Cabranes A, Venderova K, de Lago E, et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005;20:207-217.PubMedCrossRefGoogle Scholar
  91. 91.
    Koch M, Mostert J, Heersema D, De Keyser J. Tremor in multiple sclerosis. J Neurol 2007;254:133-145.PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Meinck HM, Schönle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989;236:120-122.PubMedCrossRefGoogle Scholar
  93. 93.
    De Lago E, Moreno-Martet M, Cabranes A, et al. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 2012;62:2299-2308.PubMedCrossRefGoogle Scholar
  94. 94.
    Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord 2015;30:313-327.PubMedCrossRefGoogle Scholar
  95. 95.
    Buccellato E, Carretta D, Utan A, et al. Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis. J Ethnopharmacol 2011;133:1033-1038.PubMedCrossRefGoogle Scholar
  96. 96.
    Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-1526.PubMedCrossRefGoogle Scholar
  97. 97.
    Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-441.PubMedCrossRefGoogle Scholar
  98. 98.
    Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs 2011;25:187-201.PubMedCrossRefGoogle Scholar
  99. 99.
    Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62:1105-1109.PubMedCrossRefGoogle Scholar
  100. 100.
    Koppel BS, Brust JCM, Fife T, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:1556-1563.PubMedCentralPubMedCrossRefGoogle Scholar
  101. 101.
    Berrendero F, Sanchez A, Cabranes A, et al. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 2001;41:195-202.PubMedCrossRefGoogle Scholar
  102. 102.
    Martin JB. Huntington’s disease: new approaches to an old problem. The Robert Wartenberg lecture. Neurology 1984;34:1059-1072.PubMedCrossRefGoogle Scholar
  103. 103.
    Folstein SE, Leigh RJ, Parhad IM, Folstein MF. The diagnosis of Huntington’s disease. Neurology 1986;36:1279-1283.PubMedCrossRefGoogle Scholar
  104. 104.
    Lastres-Becker I, Hansen HH, Berrendero F, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington’s disease. Synapse 2002;44:23-35.PubMedCrossRefGoogle Scholar
  105. 105.
    Pazos MR, Sagredo O, Fernández-Ruiz J. The endocannabinoid system in Huntington’s disease. Curr Pharm Des 2008;14:2317-2325.PubMedCrossRefGoogle Scholar
  106. 106.
    Makowiecka J, Wielgus K. Therapeutic potential of cannabinoids—perspectives for the future. J Nat Fibers 2014;11:283-311.CrossRefGoogle Scholar
  107. 107.
    Richfield EK, Herkenham M. Selective vulnerability in Huntington’s disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 1994;36:577-584.PubMedCrossRefGoogle Scholar
  108. 108.
    Sandyk R, Consroe P, Stern LZ, et al. Effects of cannabidiol in Huntington’s disease. Neurology 1986;36:342.Google Scholar
  109. 109.
    Zhornitsky S, Potvin S. Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals 2012;5:529-552.PubMedCentralPubMedCrossRefGoogle Scholar
  110. 110.
    Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 1991;40:701-708.PubMedCrossRefGoogle Scholar
  111. 111.
    Muller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington’s disease. Mov Disord 1999;14:1038-1040.PubMedCrossRefGoogle Scholar
  112. 112.
    Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington’s disease. J Neuropsychiatry Clin Neurosci 2006;18:553-554.PubMedCrossRefGoogle Scholar
  113. 113.
    Chesher GB, Consroe P, Musty RE. Marijuana: an international research report. In: Proceedings of the Melbourne Symposium on Cannabis, 2–4 September 1987. Government Publishing Service, Canberra, 1988.Google Scholar
  114. 114.
    Curtis A, Mitchell I, Patel S, et al. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov Disord 2009;24:2254-2259.PubMedCrossRefGoogle Scholar
  115. 115.
    Sagredo O, Pazos MR, Satta V, et al. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease. J Neurosci Res 2011;89:1509-1518.PubMedCrossRefGoogle Scholar
  116. 116.
    Sagredo O, Ruth Pazos M, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat CNS Drug Discov 2012;7:41-48.PubMedCrossRefGoogle Scholar
  117. 117.
    DeSanty KP, Dar MS Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice. Pharmacol Biochem Behav 2001;69:251-259.PubMedCrossRefGoogle Scholar
  118. 118.
    Patel S, Hillard CJ. Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 2001;297:629-637.PubMedGoogle Scholar
  119. 119.
    Wang X, Whalley BJ, Stephens GJ. The du(2J) mouse model of ataxia and absence epilepsy has deficient cannabinoid CB1 receptor-mediated signalling. J Physiol 2013;591:3919-3933.PubMedCentralPubMedCrossRefGoogle Scholar
  120. 120.
    Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 2012;133:79-97.PubMedCrossRefGoogle Scholar
  121. 121.
    Mievis S, Blum D, Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 2011;42:524-529.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2015

Authors and Affiliations

  • Shokouh Arjmand
    • 1
  • Zohreh Vaziri
    • 1
  • Mina Behzadi
    • 1
  • Hassan Abbassian
    • 1
  • Gary J. Stephens
    • 2
    Email author
  • Mohammad Shabani
    • 1
    Email author
  1. 1.Kerman Neuroscience Research Center, Neuropharmacology InstituteKerman University of Medical SciencesKermanIran
  2. 2.School of PharmacyUniversity of ReadingReadingUK

Personalised recommendations